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Abstract 
 
Primary sclerosing cholangitis (PSC) is an idiopathic cholangiopathy strongly associated with 
inflammatory bowel disease (IBD) and characterized by cholestasis, chronic immune infiltration 
and progressive fibrosis of the intrahepatic and extrahepatic bile ducts. PSC confers a high risk 
of cholangiocarcinoma (CCA) with PSC-CCA representing the leading cause of PSC-associated 
mortality. PSC-CCA is derived from cholangiocytes and associated progenitor cells – a 
heterogeneous group of dynamic epithelial cells lining the biliary tree that modulate the 
composition and volume of bile production by the liver. Infection, inflammation and cholestasis 
can trigger cholangiocyte activation leading to an increased expression of adhesion and antigen-
presenting molecules as well as the release of various inflammatory and fibrogenic mediators. As 
a result, activated cholangiocytes engage in a myriad of cellular processes, including 
hepatocellular proliferation, apoptosis, angiogenesis and fibrosis. Cholangiocytes can also 
regulate the recruitment of immune cells, mesenchymal cells, and endothelial cells that 
participate in tissue repair and destruction in settings of persistent inflammation. In PSC, the role 
of cholangiocytes and the mechanisms governing their transformation to PSC-CCA are unclear 
however localization of disease suggests that cholangiocytes are a key target and potential 
regulator of hepatobiliary immunity, fibrogenesis and tumorigenesis. Herein, we summarize 
mechanisms of cholangiocyte activation in PSC and highlight new insights into disease pathways 
that may contribute to the development of PSC-CCA. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 4 
1.  Introduction 
 
Primary sclerosing cholangitis (PSC) is a rare hepatobiliary disease characterized by persistent 
biliary inflammation, concentric periductal fibrosis (“onion-skin” fibrosis) and in most cases, 
progression to liver cirrhosis and end-stage liver disease. PSC carries a significant risk of 
cholangiocarcinoma (CCA) and PSC-CCA represents the most significant cause of patient 
mortality in PSC [1,2]. By contrast, risk of hepatocellular carcinoma (HCC) is relatively low in 
PSC [3,4] and underscores the central role of cholangiocytes in the pathogenesis of disease. PSC 
shows a male preponderance (2 to 1) and affects all ages with a median onset of 30 – 40 years. 
Incidence ranges geographically from 0 – 1.3 cases per 100,000 persons per year and prevalence 
from 0 – 16.2 cases per 100,000 persons [5,6]. In the majority of cases, PSC associates with a 
distinct form of inflammatory bowel disease (IBD) that bears unique clinical [7] and genetic 
features to ulcerative colitis and Crohn’s disease [8-10]. Up to 25% of PSC patients also develop 
autoimmune conditions, including autoimmune thyroid disease, type 1 diabetes, rheumatoid 
arthritis and celiac disease [11]. Heritability is comparable to other complex immune-mediated 
disorders as first-degree relatives are approximately 10-times more likely to develop PSC 
compared to unrelated individuals [12]. Definitive diagnosis of PSC is achieved by findings of 
characteristic biliary strictures using magnetic resonance- or endoscopic retrograde- 
cholangiography (MRCP/ERCP) following the exclusion of secondary sclerosing cholangitis 
etiologies (e.g. IgG4-associated cholangitis, infections, ischemia, toxins, biliary calculi or 
trauma) [13]. Owing to a lack of effective medical therapies [14-16], over 50% of patients 
progress to end-stage disease within 10-15 years of diagnosis which positions PSC as the leading 
indication of orthotopic liver transplantation amongst cholestatic diseases in Western countries 
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[17,18]. Following transplantation, the 1-year survival rate is 85%, the 5-year survival rate is 
72% (United Network for Organ Sharing; www.unos.org) with disease recurring in 
approximately 25% of cases [19,20]. 
 
The localization of immune infiltrate and fibrosis surrounding portal areas strongly suggests that 
cholangiocytes are key players in PSC, either as a victim or a foe – or both. Cholangiocytes are a 
heterogeneous group of reactive epithelial cells that line the intrahepatic and extrahepatic bile 
ducts as well as the peribiliary glands and facilitate the transport of bile constituents from the 
liver to the duodenum [21,22]. Cholangiocytes express a variety of molecular transporters, 
aquaporins and ion channels that also enable cholangiocytes to modify the final composition and 
volume of bile entering the biliary tract [18,23-25]. In PSC, cholangiocytes lining both the 
intrahepatic and extrahepatic ducts can be affected and inflammation of the biliary tract is linked 
to cholangiocyte senescence and cholestasis [26,27]. There is also precursor cell activation, with 
an expansion of the peribiliary gland compartment and likely (although formally not shown) 
increased mucus production [22]. Impaired cholangiocyte function resulting from a combination 
of biliary insults (likely involving both inflammation, bile acid toxicity and microbial factors) 
likely contributes to PSC pathogenesis. It is currently unknown to what extent disturbances in 
normal cholangiocyte functions are involved in PSC causation, however as shown by sclerosing 
cholangitis in the context of mutations to the cholangiocyte proteins cystic fibrosis 
transmembrane conductance regulator (CFTR) [27,28], X-prolyl aminopeptidase P1 (XPNPEP1) 
and adducing 3 (ADD3) [29-33], the possibility exists. As it stands, the precise etiopathogenesis 
of PSC is unknown and what we currently believe is that a complex manifestation of multiple 
genetic and environmental determinants in sum results in the clinical phenotype [34-39]. 
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Similarly, the mechanisms that precipitate the malignant transformation of cholangiocytes in 
PSC-CCA are poorly understood and it remains to be determined what proportion of PSC-CCA 
results from the interaction of genetic and environmental factors that initiate PSC versus 
secondary effects related to cholangiocyte activation, chronic inflammation, bile acid toxicity 
and cellular senescence that occur during the progression of disease. 
 
 
2. Epidemiology of PSC-CCA 
 
CCA is an adenocarcinomatous cancer arising from cholangiocytes. Overall, CCA is rare and 
accounts for approximately 3% of all gastrointestinal tumors worldwide [40-43]. PSC is a major 
risk factor for CCA with 10% of CCA cases in the Western world being associated with PSC 
[44,45]. In patients with PSC, the annual incidence of PSC-CCA is 0.5 – 1.5% [46-48] and the 
lifetime risk ranges from 6 – 12% [2,45-52]. Higher frequencies of PSC-CCA (up to 19.9 %) are 
reported in transplant and referral center cohorts but such studies presumably include a greater 
number of patients with severe PSC phenotypes and likely overestimate the true prevalence of 
PSC-CCA in the total patient population [46,53]. Similarly to the overall incidence of PSC [54-
56], risk of PSC-CCA is higher in northern Europe and the United States than populations in 
southern Europe and Asia (2.8 % to 8.4%) [50,57,58]. Pediatric patients and patients with small 
duct PSC also have a lower risk of PSC-CCA [59-61]. Approximately one third of PSC-CCA is 
diagnosed within the first year of PSC diagnosis suggesting that undiagnosed PSC precedes the 
development of PSC-CCA in these cases with symptoms primarily related to PSC-CCA leading 
to the diagnosis of PSC [2,47,59,62].  
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Knowledge on predisposing risk factors for PSC-CCA are scarce. The duration and severity of 
PSC do not seem to correlate with PSC-CCA development [48,63,64] and several proposed 
factors, including age at diagnosis, smoking and alcohol consumption, a Mayo risk score of more 
than four, a history of variceal bleeding or colorectal neoplasia and the presence or duration of 
concurrent IBD confer only small increments to disease liability and fail to stratify PSC 
subgroups at high risk for PSC-CCA [48-51,65,66]. Several studies support a model of CCA 
development whereby inflammatory epithelial damage leads to a sequence of metaplasia to low 
grade dysplasia (LGD), high grade dysplasia (HGD) and carcinoma (Figure 1) [63,67-71]. In 
agreement with this model, cholangiocytes in explant livers from PSC-CCA patients more often 
show evidence of metaplasia (43% vs 19%, P = 0.013) and dysplasia (83% vs 36%, P < 0.0001) 
than in PSC without CCA suggesting an association between biliary dysplasia and PSC-CCA 
[71-73]. Supporting this notion, polysomy and homozygous loss of 9p21 indicative of bile duct 
dysplasia and CCA have been observed with increasing frequencies in HGD than LGD [74,75]. 
Thus, cholangiocyte dysplasia may serve as a predictor for PSC-CCA, however dysplasia is also 
relatively frequent in the absence of PSC-CCA and may regress after resolution of biliary tract 
infections [71,76,77]. Moreover, the mechanisms regulating the progression from inflammatory 
epithelial damage to neoplastic transformation are largely unknown however surveillance for 
cholangiocarcinoma is recommended for patients with PSC (Figure 2). 
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3. Genetics of PSC and PSC-CCA 
 
To date, 23 susceptibility loci of genome-wide significance (P ≤  5.0 ×10-8) and several loci of 
suggestive significance have been identified in PSC (Table 1) [35,77-79]. The genetic 
architecture in PSC mimics that of prototypical antigen-driven conditions such as rheumatoid 
arthritis, type 1 diabetes and celiac disease with the by far strongest association residing within 
the human leukocyte antigen (HLA) complex. Non-HLA associations in PSC also overlap with 
other complex immune-mediated conditions and largely correspond to pathways of immune 
function, trafficking and tolerance suggesting that patients with PSC carry an underlying 
predisposition towards autoimmunity that precedes other biliary insults including those involving 
increased gut permeability and toxic accumulation of bile acids [8-10,76]. The presence of 
distinct T-cell clonality [80,81] and antibody production in the liver [76,82] further implicate 
PSC as an immune-mediated entity and supports a disease model where antigens of unknown 
origin presented on disease-associated HLA molecules drive the activation of pathogenic T cells 
and B cells [35,83]. Thus far, the antigenic sources in PSC have not been identified but given 
that most patients appear unresponsive to immunosuppressive therapy [84-87], a continuous 
exposure to a diverse variety of exogenous antigens (infectious, dietary, environmental) may 
underpin the development of biliary inflammation in PSC. Such a disease mechanism would be 
analogous to celiac disease where dietary antigens from cereal gluten proteins are necessary to 
trigger B- and T-cell reactivity to self-antigens and ultimately gut epithelium destruction [88-90]. 
 
As non-HLA risk regions primarily point to the relevance of immune pathways [35,91,92], 
development of PSC-CCA could most likely serve a secondary event related to the disease 
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process and not result from a primary genetic effect. This does not exclude the possibility that 
the current identified risk loci have undefined roles in cholangiocyte biology and play relevant 
roles in carcinogenic processes [35,93]. Delineating such pathophysiological implications in PSC 
will require further translational studies. For example, the MST1 gene at chromosome 3p21, 
which represents one of the strongest susceptibility loci outside the HLA-region in PSC (Table 
1), encodes a serine-threonine kinase involved in cell proliferation, apoptosis and tumour 
suppression in the liver [62,65,94,95]. MST1 variants have been implicated in the risk of sporadic 
extrahepatic CCA [96,97], moreover MST1 has been shown to suppress hepatocellular 
carcinoma development through the suppression of the YAP1 oncogene [65,96]. Thus, the role of 
MST1 in the context of cancer development and PSC-CCA merits further investigation. The 
BCL2L11 risk locus at 2q13 serves as another example of a putative combined PSC and PSC-
CCA risk locus. BCL2L11 encodes the BCL-2-Like protein-11 (BCL2-L-11) and marked BCL2-
L-11 overexpression has been shown in CCA tissue from rats [98,99]. BCL2-L-11 is critical for 
apoptosis of B-and T cells, granulocytes and macrophages [96,100] and the early induction of 
BCL2-L-11 may eliminate cytotoxic T cells prematurely resulting in chronic inflammation and 
tumour progression [101-103]. CTLA4 at 2q33 represents another plausible PSC candidate risk 
gene of interest in the context of PSC-CCA. Surface expression of CTLA-4 is present on a 
variety of human malignant solid tumours [104,105] and CTLA-4 may induce immune 
dysregulation as antibodies blocking CTLA4 have been utilized as checkpoint inhibitors in 
cancer immunotherapy [106,107]. Interestingly, the antitumor effects from CTLA4 inhibition 
may rely on the composition of the gut microbiome as tumours in germ-free mice do not to 
respond to CTLA4 blockade [108]. Other PSC candidate risk genes with putative roles in 
carcinogenesis based on insight from other diseases or animal models include FOXP1, NFKB1, 
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CD226 and STRN4 (Figure 3), and future investigation is required to elucidate the impact of 
specific genetic variants within these and other established risk genes identified in the general 
PSC population in the PSC-CCA subpopulation. 
 
Lastly, a limited number of studies exploring the contribution of non-PSC risk loci known to 
confer an increased risk for PSC-CCA susceptibility have been performed. Two polymorphisms 
of the natural killer cell receptor G2D (NKG2D) have been implicated in PSC-CCA in a 
Scandinavian PSC cohort (rs1105378, OR = 2.08, P = 0.011 and rs2617167, OR = 2.32, P = 
0.0020) [109]. NKG2D is an activating receptor expressed on the surface of natural killer (NK) 
cells, invariant natural killer T (NKT) cells, CD8+
 
T cells and subsets of CD4+ T cells [110]. In 
healthy tissue, NKG2D ligands are generally absent on the cell surface, but can be expressed at 
sites of inflammation and on cells that have undergone hyper-proliferation and transformation. 
Although the precise role of the NKG2D variants associated with PSC-CCA needs to be 
confirmed, these variants may impair NKG2D surveillance and recognition of the NKG2D 
ligand; major histocompatibility complex class I chain-related molecule A (MICA). The MICA 
5.1 allele is associated with PSC and carriership of this particular variant is associated with PSC-
CCA resistance (OR = 0.43, 95%, P = 0.032) [109,111]. It is possible that MICA 5.1 interactions 
with low-risk NKG2D alleles provide protection against PSC-CCA [109]. Suggestive 
associations to genetic variants within the DNA repair genes MutY homology (MUTYH) and 
Nei-like DNA glycosylase 1 (NEIL1) have been implicated with PSC-CCA development [112].  
 
Genetically-driven subsets of PSC are likely to exist, including phenotypes associated with a 
higher risk of PSC-CCA development, and studies focusing on this yet undefined high-risk PSC-
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CCA subset may reveal oncogenic mutations hitherto not identified at robust significance levels 
in the overall PSC population. Exome and/or whole genome sequencing studies not yet 
performed in PSC may also reveal rare sequence variants with strong phenotypic effects 
contributing to risk of PSC-CCA [113]. 
 
 
4. Cholangiocyte heterogeneity in PSC and PSC-CCA 
 
Cholangiocytes are heterogeneous and differences in their morphology, function and ontogeny 
may relate to PSC phenotypes and development of PSC-CCA (Figure 4). Intrahepatic ducts are 
mostly comprised of small cholangiocytes and demonstrate a flattened or cuboidal morphology 
with microvilli extending towards the biliary lumen [114,115]. By contrast, large cholangiocytes 
found mainly in the extrahepatic bile ducts appear columnar and project a primary cilium on the 
apical surface which is capable of sensing chemical and mechanical stimuli of the biliary lumen 
[116]. Morphological distinctions amongst small and large cholangiocytes also reflect 
differences in embryological origin as small cholangiocytes are thought to originate from a 
shared hepatoblast precursor whereas large cholangiocytes share a common pancreaticoduodenal 
progenitor [114,117]. Although perihilar CCA is topographically the most common subtype of 
PSC-CCA (~ 65%), primary tumors may less frequently arise from cholangiocytes lining the 
large intrahepatic (15%) and extrahepatic (20%) bile ducts [118]. 
 
The role of small versus large cholangiocytes in the development of PSC-CCA is unclear 
however PSC-CCA is predominantly thought to originate from large cholangiocytes lining 
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intrahepatic and extrahepatic bile ducts [1,2,119] and data from animal models of chronic liver 
injury show that large cholangiocytes undergo greater levels of proliferation [120] and apoptosis 
[121] compared to small cholangiocytes. Additionally, damage to bile ducts can also trigger a 
reparative process known as ductular reaction which features the proliferation and expansion of 
bile ducts and induction of liver progenitors that can differentiate into both hepatocytes and 
cholangiocytes [122]. Taken together, these results suggest that differential responses to biliary 
stimuli and injury may explain the higher incidence of PSC-CCA amongst patients with large 
duct PSC compared to those with small duct disease. Ongoing efforts towards defining the 
specific roles of small and large cholangiocyte in various biological pathways may uncover 
important mechanisms underlying disease progression and development of PSC-CCA. 
 
 
5. Dysbiosis and the gut-liver axis 
 
Understanding the initiating and propagating factors responsible for cholangiocyte activation in 
PSC is of considerable interest given that cholangiocytes have the dynamic capacity to detect a 
multitude of stimuli and broadly influence various immune cells that may resolve biliary injury 
but also contribute to cholangiopathy in an inflammatory context [123]. Similar to, and in 
continuity with the intestinal epithelium, cholangiocytes are often considered a first-line of 
defense with relevant functional capacities (e.g. expression of pathogen pattern recognition 
receptors [PRRs]) that including the transmembrane family of Toll-like receptors (TLRs) and 
intracellular proteins containing the nucleotide binding oligomerization domain (NOD) 
[124,125] enables cholangiocytes to recognize a variety of pathogenic molecules and 
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endogenous components released from host cells following infection and cellular injury [126]. 
TLR and NOD ligation initiates the translocation of the pleiotropic transcription factor NF-B 
and signaling through the mitogen-activated protein kinase (MAPK) cascade, both of which lead 
the production of inflammatory chemokines/cytokines, upregulation of surface adhesion 
molecules as well as the activation of pathways regulating cell growth, apoptosis and 
tumorigenesis [127]. Dysregulation of the NF-B1 pathway may contribute to biliary 
inflammation and development of PSC-CCA as NF-B subunit 1 (NF-B1) has been identified 
as a PSC risk loci (Table 1) [9]. However, no direct assessments of NF-B or MAPK signaling 
have been conducted in PSC and further assessment of these pathways, preferably in primary 
cholangiocytes from patients and healthy subjects, is necessary to substantiate any such 
involvement. 
 
Several lines of emerging evidence argue that microbes in the gut and/or biliary tract participate 
in the activation of cholangiocytes and development of PSC-CCA. Gut commensals are known 
to affect bile acid metabolism [128,129] and dysbiosis identified in fecal and mucosal patient 
samples highlights that altered or reduced microbial diversity is a risk factor in PSC [34,36-39]. 
Supporting this concept, an absence of commensal microbiota in the multidrug resistance 2 
knockout (mdr2
-/-
) murine model of PSC exacerbates hepatobiliary disease and further suggests a 
role for microbiota in the pathogenesis of PSC [130]. A scenario in PSC may exist whereby gut 
dysbiosis leads to an altered metabolism of primary bile acids and dysfunctional reabsorption of 
secondary bile acids across the colonic epithelium [131]. Dysbiosis in chronic liver disease has 
also been shown to alter systemic levels of secondary bile acids and the accumulation of 
secondary bile acids in the enterohepatic circulation is suspected to contribute to liver cirrhosis 
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development [132] and is also noted in patients with colon cancer [133]. Hence, a positive 
feedback mechanism initiated by PRR signaling in cholangiocytes and enhanced by the intrinsic 
toxicity of biliary constituents may lead to dysbiosis and an even greater accumulation of toxic 
bile acids within the enterohepatic circulation. 
 
 
6. Cholangiocyte immunobiology in the progression of PSC 
 
Cholangiocytes play an integral role in the regulation of liver immunity and upregulate the 
expression of adhesion molecules and proinflammatory signals that orchestrate the recruitment 
and activation of innate and adaptive immune cells [104]. Based on the localization of 
lymphocytes and expression of adhesion molecules (Figure 5), cholangiocytes appear to interact 
with CD4+ and CD8+ T cells, but no convincing evidence of antigen-dependent activation has 
thus far been demonstrated in PSC. Resting cholangiocytes are known to constitutively express 
high levels of HLA class I [18,23] and can activate NKT cells, a subset of innate-like T cells 
which recognize lipid antigens presented on the HLA class I-like molecule CD1d [19]. Upon 
activation, cholangiocytes are known to express detectable levels of HLA class II molecules 
[134,135] and the adhesion molecules intracellular cell adhesion molecule-1 (ICAM-1) and 
lymphocyte function-associated antigen-3 (LFA-3) which enable the direct interaction of T cells 
and cholangiocytes via LFA-1 and CD2 [18,23,25]. However, it remains debatable if 
cholangiocytes possess the appropriate repertoire of co-stimulatory molecules necessary to 
activate conventional T cells in an antigen-dependent manner as cholangiocytes do not express 
the B7 family members B7.1 (CD80) and B7.2 (CD86). These important co-stimulatory 
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molecules engage CD28 and CTLA-4 expressed on T cells and are widely regarded as the 
prototypical signature of professional antigen-presenting cells [26]. Whilst future data is needed 
to clarify if cholangiocytes present endogenous or exogenous peptide antigens to conventional T 
cells, the proximity of lymphocytes around portal areas in PSC may in fact support a model 
where lymphocytes activated from the gut or draining lymph nodes traffic to the liver [136] and 
target reactive cholangiocytes due to their expression of proinflammatory cytokines [27]. 
 
In addition to conventional T lymphocytes, NK cells, NKT cells and macrophages are likely to 
contribute to the inflammatory setting in PSC given these cell types interact with hepatic stellate 
cells (HSCs) and regulate the remodeling of the local biliary microenvironment during liver 
fibrosis and wound healing (Figure 5) [29,31-33]. Liver macrophages in particular are likely to 
play an integral role in PSC as alterations to the gut microflora leading to an increase of gut 
permeability and bacterial translocation into the enterohepatic circulation [34,36-39] presumably 
results in the activation of macrophages and secretion of pro-inflammatory and fibrogenic 
cytokines [40,42]. Recent data also suggests that mucosal-associated invariant T (MAIT) cells, 
an innate-like T cell subset, may participate in PSC as cholangiocytes and liver B cells exposed 
to bacterial components upregulate the antigen receptor for MAIT cells known as MR1 and 
induce MAIT cell activation in an MR1-dependent, cytokine-independent fashion [44]. 
 
The pathognomonic lesion in PSC is characterized by an accumulation of fibroblasts and matrix 
deposition around the biliary epithelium. Cholangiocarcinoma in PSC also shows excessive 
“scirrhous” features, suggesting that interactions between the mesenchymal and cholangiocyte 
compartment are relevant in both PSC development and the associated neoplastic cholangiocyte 
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transformation. Local secretion of pro-inflammatory cytokines, such as inducible nitric oxide 
synthase (iNOS), promotes nitric oxide (NO) production and IL-6 from cholangiocytes and 
surrounding cells, leading to cholangiocyte proliferation and oxidative DNA damage [46]. iNOS 
expression is significantly upregulated in both PSC and PSC-CCA cholangiocytes as a result of 
the secretion of pro-inflammatory cytokines such as TNF- in the microenvironment [46]. In 
oxidative DNA-damaged cholangiocytes, 8-oxodeoxyguanine represents the most abundant 
oxidative DNA lesion [46]. NO counteracts effective DNA repair by inhibiting 8-
oxodeoxyguanine base excision allowing for the excessive accumulation of oxidative 8-
oxodeoxyguanine and further promotion of DNA damage and putatively malignant 
cholangiocyte transformation [54]. 
 
Production of IL-6 via gp130, a co-receptor for IL-6, leads to activation of IL-6/STAT3 signaling 
in cholangiocytes which in turn promotes the proliferation of malignant cholangiocytes by p38 
and p42/44 MAPK [57]. In addition IL-6 may trigger activation of yes-associated protein (YAP) 
and Notch, transcriptional regulators that control cell growth and regeneration independently of 
the gp130 effector IL-6/STAT3 pathway [59]. In mucosal injury, intestinal gp130/IL-6 signaling 
stimulates epithelial cell proliferation and causes aberrant differentiation, and it can be 
speculated if sustained YAP-expression may lead to excessive and oncogenic cholangiocyte 
proliferation in the setting of biliary epithelial injury in PSC [59,62]. In a murine model biliary 
transduction of constitutively active YAP combined with bile duct ligation and IL-33 
administration lead to CCA formation [63]. Interestingly, the PSC risk gene MST1 (Table 1), has 
been implicated in regulating YAP activation [65]. The biliary mitogen IL-33 has also been 
implicated in cholangiocyte carcinogenesis by promoting downstream activation of IL-6 and 
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inflammation and fibrosis of the biliary tract [63,67]. After neoplastic transformation, 
cholangiocytes secrete a range of mediators such as platelet-deriver growth factor-D (PDGF-D) 
which induce a stromal reaction promoting further tumor growth and invasiveness. PDGF-D 
recruits cancer-associated fibroblasts to the stroma, which release vascular endothelial growth 
factor-C (VEGF-C) that stimulates lymphangiogenesis and may promote lymphatic spread of 
tumors [72,73]. 
 
 
7. Cholestasis and bile acid toxicity in malignant cholangiocyte development in PSC 
 
Some lines of evidence suggest that the cholestasis that occurs in the setting of PSC is critical for 
CCA development. In cholestasis, bile acids accumulate and exert abnormal effects on 
cholangiocytes. In particular, accumulation of the bile acid component deoxycholic acid 
activates epidermal growth factor receptor (EGFR), an upstream activator of Ras in 
cholangiocytes [74]. EGFR has been implicated in the growth of neoplastic cholangiocytes and 
several studies has shown increased expression and activating mutations of EGFR in sporadic 
CCA [76,77]. Sustained activation of EGFR via a TGF--dependent mechanism in CCA induces 
expression of cyclooxygenase-2 (COX-2) and p38 and p42/44 MAPK and activation of this 
pathway may contribute to CCA [77,78]. Lipopolysaccharide (LPS) which is frequently elevated 
in chronic liver disease has been shown to transactivate EGFR through release of TGF- [76]. 
Furthermore, it has been demonstrated that phosphorylated EGFR is elevated in PSC and that 
LPS-induced Ras activation correlates with levels of EGFR phosphorylation, observations that 
putatively link EGFR to malignant cholangiocyte transformation in PSC [80].   
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Presence of deoxycholic acid in addition prolongs the activity of myeloid-cell leukemia-1 (Mcl-
1), an anti-apoptotic member of the B-cell leukemia-2 family [137]. Mcl-1 promotes cellular 
proliferation and participates in tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL)-mediated resistance in CCA putatively via the IL-6/protein kinase B (Akt) signaling 
pathway [83]. In the setting of biliary tract inflammation, oxygenated derivatives of cholesterol 
(oxysterols) are abundant in bile acids and induces sustained COX-2 expression and putatively 
malignant cholangiocyte transformation by promoting cell proliferation, angiogenesis and 
inhibition of apoptosis [84,86,87]. Oxysterol-accumulation in bile may also lead to induction of 
the cancer-related hedgehog signaling pathway [88,90]. Alluding to the previously described 
relevance of oxidative stress and DNA damage in biliary tract carcinogenesis, the bile acid 
glycochenodeoxycholate has been shown to induce oxidative stress and DNA damage in 
cholangiocytes using experimental models [91].   
 
 
8. MicroRNAs in PSC and PSC-CCA 
 
MicroRNAs (miRNAs) are evolutionarily-conserved endogenous non-coding RNAs that target 
complementary binding sites in the 3’-untranslated region (UTR) of coding RNAs to regulate 
post-transcriptional gene expression [93]. Emerging data from many autoimmune and chronic 
inflammatory disorders [94,95] implicate the expression of specific miRNAs in the initiation and 
progression of disease. Little is known about miRNAs in PSC however a recent study reported 
decreased miR-200C in PSC compared to healthy subjects, increased miR-483-5p and miR-194 
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in PSC-CCA, and elevated miR-222 and miR-483-5p in PSC-CCA compared to patients with 
PSC alone [96]. These findings suggest that specific miRNAs in PSC and PSC-CCA may serve 
as useful biomarkers for the stratification of PSC phenotypes. In addition to diagnostic 
applications, transcriptomic miRNA profiling may also provide insights into the pathogenesis 
and oncogenesis of PSC. For example, decreased miR-200C expression in PSC [96] may 
contribute to the increased risk of PSC-CCA since the inactivation of miR-200c is known to 
trigger epithelial-mesenchymal transition in CCA [98]. By contrast, elevated miR-194 and miR-
483-5p in PSC-CCA [96] could represent the activation of tumour suppressor pathways given 
that both miRNAs have been shown to strongly repress epithelial-mesenchymal transition and 
colonization of metastases in the liver [101,103]. Future transcriptomic approaches utilizing bile 
or liver mononuclear cells from large, well-defined PSC cohorts may identify miRNAs in PSC 
and PSC-CCA that point towards novel disease pathways that are targetable by new and existing 
therapeutics strategies. 
 
 
9. Chronic biliary inflammation leads to cholangiocyte apoptosis, senescence and 
senescence-associated secretory phenotype (SASP) in PSC 
 
Whilst the responsiveness of cholangiocytes to exogenous and endogenous stimuli is well 
documented [104], the direct relationship between cholangiocyte activation and the 
etiopathogenesis of PSC remains unclear. Persistent cholangiocyte activation in cholangiopathies 
such as PSC is known to increase apoptosis [106] which eliminates cells that have accumulated 
DNA damage and is important mechanism for inhibiting cancer development [138,139]. 
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Apoptosis can be suppressed by mutations that dysregulate the tumour suppressor p53 and 
overexpression of p53 is reported in cholangiocytes from patients with PSC-CCA [69]. p53 
mutations contributes to CCA development by dysregulating DNA repair and cell cycle arrest 
and by suppressing the normal apoptotic response [140]. Death signal mediated by binding of 
(TRAIL to TRAIL-R2/death receptor 5 (DR5) has also been implicated in cholestatic liver 
injury. Human cholangiocytes constitutively express DR5, and TRAIL expression and apoptosis 
has been shown to be significantly elevated in cholangiocytes in PSC [141,142]. TRAIL has 
been reported to promote the migration and invasiveness of CCA via a nuclear-factor B (NF-
B)-dependent pathway in human cholangiocarcinoma cell lines [141]. Furthermore, treatment 
with sub-lethal concentrations of TRAIL has been shown to be mutagenic putatively by inducing 
misrepair of DNA damaged cholangiocytes and chromosomal instability [143].  
 
Chronic cholangiocyte activation in PSC can also initiate a process known as cellular senescence 
whereby cholangiocytes enter a state of permanent cell cycle G1 arrest to limit the proliferation 
of damaged cells at high risk of malignant transformation [101]. Cholangiocytes from PSC 
patients feature a higher expression of senescence markers, including -galactosidase (SA--
GAL), p16
INK4a
 and N-Ras compared to cholangiocytes from patients with primary biliary 
cholangitis (PBC) and hepatitis C [27] indicating that cholangiocyte senescence may be a key 
process in the progression of PSC. Prolonged stimulation can also induce the transition of 
senescent cells to a highly pro-inflammatory and potentially pathogenic state known as 
senescence-associated secretory phenotype (SASP) [101]. SASP in PSC is associated with the 
robust secretion of cytokine/chemokines (IL-6, IL-8, CCL2, PAI-1), various growth factors and 
matrix metalloproteases (MMPs) that trigger endothelial cell invasion [144] and promote 
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tumorigenesis in models of epithelial cancer [145,146]. The production of these molecules in 
combination with the presence of endogenous (cholestane-3,5,6-oxysterol) and exogenous (LPS) 
bile constituents can also induce bystander senescence and amplify SASP in the biliary tract 
[27]. Thus, pharmacologic inhibition of cholangiocyte senescence may represent a novel 
therapeutic approach in PSC as inhibition of N-Ras activation by farnesylthiosalicylic acid 
reduced the expression of SA--GAL on PSC cholangiocytes activated by LPS [27]. The long-
term consequences of cholangiocyte senescence in the pathophysiology of PSC remains to be 
explored, but SASP induction could represent an integral link between intestinal dysbiosis, bile 
acid toxicity, recruitment of immune cells, liver fibrosis and development of PSC-CCA in 
patients with PSC [27] 
 
 
10.  Conclusion 
 
Over the last two decades, a better understanding of PSC and PSC-CCA has greatly increased the 
appreciation of cholangiocytes in liver physiology and disease processes. Many of these 
advances have been based on genetic findings in Mendelian cholestasis syndromes and the 
development and application of novel culture and experimental animal model systems [147,148]. 
The collective data available suggests that cholangiocytes should be considered both a primary 
target and active contributor in PSC and that chronic cholangiocyte activation can lead to the 
inhibition of apoptosis and induction of cellular senescence, processes that likely promote biliary 
damage and oncogenesis in PSC. Immunogenetic susceptibilities, a number of potentially 
relevant effector cell types and epigenetic phenomena continue to emerge as key players in PSC, 
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but the precise mechanisms underlying the activation of cholangiocytes, their role in fibrogenesis 
and their malignant transformation in PSC remains to be determined. Future studies dissecting 
known factors at an interaction with environmental factors, particularly the gut and biliary 
microbiota, in parallel with detailed mechanistic assessments of genetic and epigenetic 
determinants are likely to outline useful insights and provide the framework to prioritize 
targetable molecules and pathways for the prevention, diagnosis and treatment of PSC and PSC-
CCA. 
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Figure Legends 
 
Figure 1. Several studies support a model of primary sclerosing cholangitis-associated 
cholangiocarcinoma whereby inflammatory epithelial damage leads to sequential progression 
from normal non-dysplastic epithelium to low grade dysplasia (LGD), high grade dysplasia 
(HGD) and ultimately to invasive cholangiocarcinoma. In the clinical setting, presence of 
dysplastic changes in the biliary epithelium is commonly determined based on biliary brush 
cytology obtained from the bile ducts during endoscopic retrograde cholangiography. Shown are 
cytological and histological images and generally accepted cytological criteria to classify biliary 
brush specimens into the following categories: (i) non-dysplastic, (ii) LGD and (iii) HGD. The 
main criteria for invasiveness are histological (tumor growth beyond the basement membrane), 
as there are no clear-cut cytological criteria able to distinguish between HGD and carcinoma 
[149-151]. Cytological and histological images kindly provided by pathologists Peter Jebsen and 
Henrik M. Reims at Department of Pathology, Oslo University Hospital Rikshospitalet (Oslo, 
Norway). 
 
 
Figure 2. Suggested surveillance procedure for cholangiocarcinoma (CCA) in patients with 
primary sclerosing cholangitis (PSC). Abbreviations: AFP, alpha-fetoprotein; ERCP, 
endoscopic retrograde cholangiopancreatography, FISH; fluorescent in situ hybridization; MDT, 
multidisciplinary team, MRI/MRCP, magnetic resonance imaging/magnetic resonance 
cholangiopancreaticography; US, ultrasound. 
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Figure 3. Genetic findings highlight potential disease pathways in the etiopathogenesis of 
primary sclerosing cholangitis (PSC) and development of cholangiocarcinoma (PSC-CCA). 
PSC is a complex idiopathic cholangiopathy involving the interaction of genetic and 
undetermined environmental risk factors (dietary, microbiota, toxins). PSC risk loci identified by 
genome-wide association studies (GWAS) mainly point towards immune cell pathways (ATXN2, 
BACH2, BCL2L11, CCDC88B, CD28, CD226, CCL20, CLECK16A, CTLA4, FOXP1, GPR35, 
HDAC7, IL2, IL2RA, IL21, MST1, NFKB1, PRKD2, PSMG1, RIC8B, RFX4, SH2B3, SIK2, 
SOCS1, TNFRSF14, TCF4, UBASH3A) however several putative risk genes may be involved in 
the transformation of cholangiocytes (ATXN2, CD226, FOXP1, MUTYH, NEIL1, NFKB1, 
STRN4) and promote the development of PSC-CCA. 
 
 
Figure 4. Cholangiocyte heterogeneity is associated with distinct phenotypes of primary 
sclerosing cholangitis (PSC). Small cholangiocytes found most often in the intrahepatic ducts 
show a flattened or cuboidal morphology, large nucleus to cytoplasm ratio and microvilli that 
extend towards the biliary lumen. Large cholangiocytes located mainly in the extrahepatic bile 
ducts, appear columnar, have a small nucleus to cytoplasm ratio and project a primary cilium 
into the bile duct lumen. Cholangiocarcinoma (PSC-CCA) develops more frequently in small 
duct PSC compared to large duct PSC in patients and may reflect may reflect differential 
responses to chronic cholangiocyte activation. 
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Figure 5. Primary sclerosing cholangitis (PSC) involves a cycle of immune-mediated 
damage to the cholangiocytes leading to fibrosis and cholangiocarcinoma (PSC-CCA). 
Activated T cells and macrophage trigger the apoptosis and senescence of cholangiocytes 
resulting in the production of pro-inflammatory cytokines and chemokines that act on hepatic 
stellate cells and lead to liver fibrosis. Cholangiocyte activation can induce the upregulation of 
human leukocyte antigen (HLA) molecules but it is unknown if activated cholangiocytes directly 
stimulate T cell expansion and antibody production of B cells as disease-relevant antigens in 
PSC are unknown. Chronic cholangiocyte activation in PSC can lead to the development of PSC-
CCA, which restricts the passage of bile through the bile ducts and commonly metastasizes to the 
liver, peritoneum, intra-abdominal lymph nodes and lungs. 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Table 1. Non-HLA genome-wide significant risk loci (P ≤ 5 × 10–8) in primary sclerosing 
cholangitis. 
Putative non-HLA candidate gene(s) associated with PSC. Suspected functions of the candidate 
genes are given but are based on circumstantial evidence as definitive interactions linking PSC-
associated loci to specific genes and protein functions are lacking. 
 
Risk 
locus 
Candidate risk 
gene(s) 
Reference(s) 
Putative pathophysiological implication of candidate 
gene(s) 
1p36 MMEL1, TNFRSF14 Folseraas et al. (2012) 
MMEL1: Membrane metallo-endopeptidase family. Little is 
known about its function. Potentially involved in 
neuropeptide degradation.  
TNFRSF4: Acts as a molecular switch modulating T cell 
activation and regulation of immune tolerance.  
2q13 BCL2L11 Melum et al. (2011) 
Encodes BCL-2-like protein (BCL2-L-11) which interacts 
with other BCL-2 protein family members and acts as 
apoptopic activator. Critical for apoptosis and termination of 
inflammatory responses in B and T cells, granulocytes and 
macrophages. Absence of BCL2-L-11 promotes 
autoimmunity, whereas early induction of BCL2-L-11 may 
lead to chronic inflammation and tumor progression.  
2q33 CD28, CTLA4 Liu et al. (2013) 
CD28: Co-stimulatory receptor that by binding B7 ligands 
(CD80 and CD86) is crucial for T cell activation, survival 
and proliferation. Liver-infiltrating T cells in patients with 
PSC observed to downregulate CD28 and produce higher 
levels of IFN- and TNF-. 
CTLA-4: Major negative regulator of T-cell development 
and function by binding to CD80 and CD86 in competition 
with CD28. Blockade of CTLA4 blockade has demonstrated 
gut microbiota-dependent anticancer effects.  
2q36 CCL20 Ellinghaus et al. (2016) 
Ligand for chemokine receptor CCR6. Highly expressed in 
the liver and in peripheral blood lymphocytes. Recruits 
CCR6+ lymphocytes to liver. CCL20 is expressed on 
cholangiocytes and putatively recruits IL-17-secreting 
CCR6+ T cells to the biliary epithelium.  
2q37 GPR35 Ellinghaus et al. (2013) 
Member of G-protein-coupled metabolite-sensing receptors. 
Expressed on several immune cells and subsets of gut 
epithelium. Putatively act as receptors for kynurenic acid 
and chemokine ligand 17. Kynurenic acid is a metabolite in 
the tryptophan pathway and is present in high concentrations 
in bile. Synthesis of kynurenic acid is rate-limited by the 
immune-regulatory enzyme indoleamine 2,3-dioxygenase. 
Participates in regulation of IL-4 release from natural killer 
T cells.  
3p13 FOXP1 Ji et al. (2017) 
Member of forkhead box transcription factor family. 
Relative high expression in the gut. Maintains quiescence in 
CD3+ CD4+ T cells. Involved in regulation of CD4+ 
proliferation and differentiation. May act as tumor 
suppressor. 
3p21 MST1 Melum et al. (2011) 
Serine-threonine kinase. Participates in the Hippo signaling 
pathway. High expression in liver. Involved in cell 
morphogenesis, proliferation, apoptosis and tumor 
suppression in the liver. Affects hepatocyte quiescence and 
liver size. Suppresses hepatocellular carcinoma through 
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inactivation of the YAP1 oncogene. Genetic variants in 
MST1 are associated to risk of sporadic cholangiocarcinoma.  
4q24 NFKB1 Ellinghaus et al. (2016) 
Member of NF-kappaB family. Part of the pleiotropic NF-
kappaB transcription factor family. Involved in the 
regulation of multiple biological processes including 
inflammation, tumorigenesis and apoptosis. 
4q27 IL2, IL21 Liu et al. (2013) 
IL2: Cytokine with broad range of roles in the immune 
system, among other crucial for T-cell proliferation and 
regulatory T-cell activity. Liver derived T cells from PSC 
patients produce low levels of IL-2 compared to other 
autoimmune liver diseases and healthy controls.  
IL21: Cytokine that regulates the activity of multiple target 
cells (including macrophages, natural killer cells, B- and T-
cells) in the innate- and adaptive immune response.  
6q15 BACH2 Liu et al. (2013) 
Transcription factor that regulates B-cell differentiation. 
Inhibits differentiation of effector-memory T cells. 
Implicated in the anti-viral innate immune response. 
10p15 IL2RA Srivastava et al. (2012) 
Encodes the IL-2 receptor subunit alpha (CD25), which 
binds to CD122 and forms the high-affinity receptor for IL-
2. Binds IL-2 and mediates its signaling effects. IL2RA-
deficient mice develop T-cell infiltrates in the liver and 
colon resulting in portal inflammation and colitis. 
11q13 CCDC88B Ji et al. (2017) 
Member of the hook-related protein family and regulates the 
maturation and effector functions of T cells. 
11q23 SIK2 Liu et al. (2013) 
Serine-threonine kinase that can phosphorylate HDAC7 (see 
below). Affects IL-10 in macrophages. Liver-specific SIK2 
knockdown in mice results in steatosis, insulin resistance 
and inflammation.  
12q13 HDAC7 Liu et al. (2013) 
Class IIa histone deacetylase. Highly expressed in 
CD4+CD8+ thymocytes and involved in TCR-dependent 
differentiation in the thymus. Dephosphorylation of HCDA7 
results in HDAC7-accumluation in the nucleus and 
suppression of genes essential for cytotoxic T lymphocyte 
function.  
12q23 RFX4, RIC8B Ellinghaus et al. (2016) 
RFX4: Transcription factor of the regulatory factor family. 
Potentially involved in the regulation of immune and 
infectious responses. 
RIC8B: G-alpha-binding protein that catalyzes cAMP 
production. 
12q24 SH2B3, ATXN2 Liu et al. (2013) 
SH2B3: Negative regulator of cytokine signaling and cell 
proliferation. Suppresses normal B progenitor cells by 
downregulating JAK-STAT signaling. SH2B3 associations 
have been reported in autoimmune liver diseases (PSC, PBC 
and AIH).  
ATXN2: Expressed in hepatocytes and specific neuron 
populations. Involved in EGFR trafficking and potentially 
plays a role in insulin resistance. 
16q12 CLEC16A, SOCS1 Ellinghaus et al. (2016) 
CLEC16A: Regulation of B-cell function and autophagy of 
mitochondria. 
SOCS1: Negative regulator of cytokine signaling and 
thymocyte development. Maintains regulatory T-cell 
integrity and function. Deficiency of SOCs leads to fatal 
neonatal inflammatory disease. 
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18q21 TCF4 Ellinghaus et al. (2013) 
Transcription factor that regulates plasmacytoid dendritic 
cells and early B- and T-cell development. 
18q22 CD226 Liu et al. (2013) 
Co-stimulatory surface molecule expressed on T cells and 
natural killer cells, enhancing cytotoxic function. Involved 
in a broad range of pathological processes including 
autoimmunity and cancer development. 
19q13 PRKD2, STRN4 Liu et al. (2013) 
PRKD2: Member of protein kinase D family and involved in 
regulation of cell proliferation and cytokine production via 
the NF-kappaB pathway. Required for the production of IL-
2 and IFN- after TCR engagement in peripheral T cells. 
Can phosphorylate HDAC7 (see above) which leads to 
nuclear export and inhibition of HDAC7-mediated 
transcriptional function.  
STRN4: Involved in cell differentiation, transformation and 
apoptosis by regulating protein phosphatase 2A. STRN4 
silencing suppresses malignant features of cancer cells.  
21q22 PSMG1 Liu et al. (2013) 
Chaperone protein. May be involved in altering the function 
of the ubiquitin-proteasome system and formation of the 
immunoproteosome. 
21q22 UBASH3A Ji et al. (2017) 
Member of protein tyrosine phosphatase family. Negatively 
regulates T cells by facilitating apoptosis.  
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Highlights 
 
 Genetic studies primarily highlight immune pathways as risk factors in primary sclerosing 
cholangitis (PSC). 
 
 Activation of cholangiocytes by infection, microbial products, bile acids or immune-
mediated inflammation triggers the production of cytokines/chemokine and growth factors 
involved in both biliary damage and repair. 
 
 Persistent cholangiocyte activation in PSC induces the transition of senescent 
cholangiocytes to an irreversible senescence-associated secretory phenotype (SASP) that 
promotes liver fibrosis and development of PSC-associated cholangiocarcinoma (PSC-
CCA). 
 
 Biliary tract carcinogenesis in PSC is considered a multi-step process involving the 
progression from cholangiocyte metaplasia to low grade dysplasia (LGD), high grade 
dysplasia (HGD) and ultimately invasive PSC-CCA. 
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